Abciximab (Reopro): a clinically effective glycoprotein IIb/IIIa receptor blocker

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.7, Iss.10, 1998-10, pp. : 1701-1717

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Lotrafiban: an oral platelet glycoprotein IIb/IIIa blocker

By Liu F. Craft R.M. Morris S.A. Carroll R.C.

Expert Opinion on Investigational Drugs, Vol. 9, Iss. 11, 2000-11 ,pp. : 2673-2687

Informa Healthcare

Access to resources Recommend Favorite

Platelet inhibition by abciximab is reduced in patients with the A2 allele of the glycoprotein (GP) IIb/IIIa receptor

Inpharma, Vol. 1, Iss. 1328, 2002-01 ,pp. : 20-20

Adis International

Access to resources Recommend Favorite

Clinical Pharmacokinetics of Tirofiban, a Nonpeptide Glycoprotein IIb/IIIa Receptor Antagonist: Comparison with the Monoclonal Antibody Abciximab

By Kondo K. Umemura K.

Clinical Pharmacokinetics, Vol. 41, Iss. 3, 2002-01 ,pp. : 187-195

Adis International

Access to resources Recommend Favorite

Platelet glycoprotein IIb/IIIa receptor antagonists

By Casserly I.P. Moliterno D.J.

Expert Opinion on Pharmacotherapy, Vol. 1, Iss. 3, 2000-03 ,pp. : 419-433

Informa Healthcare

Access to resources Recommend Favorite

Glycoprotein IIb/IIIa Receptor Antagonists: Clinical Pharmacology in Cardiovascular Diseases of Aging

By Sebastian M. Makkar R.

Drugs & Aging, Vol. 15, Iss. 3, 1999-09 ,pp. : 207-218

Adis International

Access to resources Recommend Favorite